Studying the effect of Coenzyme Q10 tablets on the incidence of contrast- associated acute kidney injury in patients undergoing diagnostic coronary angiography

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20260510069330N1

Enrollment

196

Registered

2026-05-13

Start date

2026-09-01

Completion date

Unknown

Last updated

2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

contrast- associated acute kidney injury. Nephropathy induced by other drugs, medicaments and biological substances

Interventions

Intervention 1: Control group: 98 patients who receive normal saline 1 cc/kg from the time of CAG until 6 hours afterward as the standard protocol for the prevention of CA-AKI. Intervention 2: Interve

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: Age over 18 years Written informed consent No contraindication to CoQ10 (such as known hypersensitivity) No history of CoQ10 supplement use

Exclusion criteria

Exclusion criteria: Patients with renal failure with GFR > 30 mL/min/1.73 m² or a history of dialysis Severe hepatic failure Active malignancy Anemia with hemoglobin level less than 10 g/dL Age over 75 years Heart failure with ejection fraction (EF) less than 30% Mean arterial pressure (MAP) less than 70 mmHg before contrast administration History of hypersensitivity to contrast medium History of recent contrast medium administration

Design outcomes

Primary

Measure	Time frame
No increase in serum creatinine. Timepoint: Measurement of serum creatinine before angiography and 72 hours after angiography. Method of measurement: Blood test.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMaryam Masoumi

Tehran University of Medical Sciences

m-masoumi@razi.tums.ac.ir+98 13 4422 1427

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Jun 11, 2026